Exagen Inc. revenue
Exagen Inc.'s revenue was $66.6m in fiscal 2025, up 19.7% on the year before. Since fiscal 2018 ($32.4m) it has grown at a compound 10.8% a year. Over the last twelve months it was $71.1m.
Revenue history
| Fiscal year | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 32 | 40 | 42 | 48 | 46 | 53 | 56 | 67 | 71 |
| Growth on the year before | — | +24.5% | +3.9% | +15.1% | −5.7% | +15.3% | +5.9% | +19.7% | — |
| Gross profit | 17 | 22 | 25 | 28 | 21 | 29 | 33 | 39 | 42 |
| Gross margin | 52.6% | 53.4% | 60.6% | 57.4% | 46.9% | 56.1% | 59.5% | 58.3% | 58.6% |
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Exagen Inc. | $71.1m | 20.8% | 10.3% |
| Personalis, Inc. | $69.7m | -13.3% | 1.2% |
| Burning Rock Biotech Ltd | $75.1m | 4.7% | — |
| Codexis, Inc. | $77.7m | 35.9% | -7.8% |
| 908 Devices Inc. | $60.8m | 13.4% | 7.5% |
| Precipio, Inc. | $60.8m | 29.5% | 43.6% |
Compare with peers
- Personalis, Inc. revenue
- Burning Rock Biotech Ltd revenue
- Codexis, Inc. revenue
- 908 Devices Inc. revenue
- Precipio, Inc. revenue
Head to head: PSNL vs XGNBNR vs XGNCDXS vs XGN
More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies